Pharma and AI firms sign $3.8 billion in deals in one month

Oct 26, 2026 · Issue 13 · 4 sources, 5 articles

AI–pharma agreements signed in October total $3.8 billion, and more than 70 alliances were formed in 2025. Among them, Pathos AI entered a development collaboration with Bristol Myers Squibb and Tempus AI.

Who is affected and how

pharmaceuticals

AI partnerships have become a standard business model; pipeline strategy must decide the balance between in-house and external AI capability.

Narrative: AI is rewriting drug development

Sources

• Big Pharma, AI Firms Sign $3.8B This Month, 70+ Alliances in 2025조선일보 · Oct 28, 2026
• Big Pharma, AI Firms Partner on Drug Developmentchosun.com · Oct 28, 2026
• Pathos Ai Enters Drug Development Collaboration with Bristol Myers Squibb and Tempus Aipharmaceutical executive · Oct 26, 2026
• Pathos Ai Enters Drug Development Collaboration with Bristol Myers Squibb and Tempus Ai | PharmExecpharmexec.com · Oct 26, 2026

Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.